Literature DB >> 21835828

Correlation between MMP1-PAR1 axis and clinical outcome of primary gallbladder carcinoma.

Xilin Du1, Shengzhi Wang, Jianguo Lu, Yizhan Cao, Nuan Song, Tao Yang, Rui Dong, Li Zang, Yuan Yang, Tao Wu, Jinmao Li.   

Abstract

OBJECTIVE: Matrix metalloprotease-1 and protease-activated receptor-1 axis plays an important role in many cancers, with activation often associated with poor survival. The aim of the present study was to determine whether the immunohistochemical detection of matrix metalloprotease-1 and protease-activated receptor-1 could provide useful information as novel therapeutic or prognostic factors in primary gallbladder carcinoma.
METHODS: Eighty-six gallbladder carcinoma tissues were evaluated by immunohistochemistry for matrix metalloprotease-1 and protease-activated receptor-1 expressions. The association of matrix metalloprotease-1 and protease-activated receptor-1 expressions with clinicopathological characteristics and the univariate survival analysis for the influence of matrix metalloprotease-1 and protease-activated receptor-1 expressions on the overall survival were analyzed.
RESULTS: Matrix metalloprotease-1 and protease-activated receptor-1 immunoreactivities were observed in 62 (72.1%) and 59 (68.6%) of the 86 gallbladder carcinoma cases, respectively. The tumors with the positive expressions of matrix metalloprotease-1 (P= 0.007) and protease-activated receptor-1 (P= 0.01) more frequently showed lymph node metastasis, respectively. In addition, the tumors with the positive expressions of matrix metalloprotease-1 and protease-activated receptor-1 tended to show a deeper invasion depth (P= 0.006 and 0.008, respectively) and more frequent lymphovascular invasion (both P= 0.01). The Kaplan-Meier survival curves demonstrated that patients with the positive expressions of matrix metalloprotease-1 and protease-activated receptor-1 had a significantly shorter survival time than those patients with their negative expression (both P= 0.02).
CONCLUSIONS: A subset of gallbladder carcinoma cases revealed the overexpression of matrix metalloprotease-1 and protease-activated receptor-1, which was associated with a progressive pathological feature and an aggressive clinical course. Therefore, matrix metalloprotease-1 and protease-activated receptor-1 expressions may be predictors for a poor prognosis in patients with gallbladder carcinoma. This is the first report describing about the involvement of matrix metalloprotease-1 and protease-activated receptor-1 axis in gallbladder carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21835828     DOI: 10.1093/jjco/hyr108

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  11 in total

1.  The polymorphism MMP1 -1607 (1G>2G) is associated with a significantly increased risk of cancers from a meta-analysis.

Authors:  Lili Lu; Yujiao Sun; Yiqun Li; Ping Wan
Journal:  Tumour Biol       Date:  2014-11-13

2.  Adjuvant treatment in biliary tract cancer: to treat or not to treat?

Authors:  Stefano Cereda; Carmen Belli; Michele Reni
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

3.  PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo.

Authors:  R Auvergne; C Wu; A Connell; S Au; A Cornwell; M Osipovitch; A Benraiss; S Dangelmajer; H Guerrero-Cazares; A Quinones-Hinojosa; S A Goldman
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

4.  Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination.

Authors:  Anna Juncker-Jensen; Elena I Deryugina; Ivo Rimann; Ewa Zajac; Tatyana A Kupriyanova; Lars H Engelholm; James P Quigley
Journal:  Cancer Res       Date:  2013-05-16       Impact factor: 12.701

5.  Matrix metalloprotease-1a promotes tumorigenesis and metastasis.

Authors:  Caitlin J Foley; Chi Luo; Katie O'Callaghan; Philip W Hinds; Lidija Covic; Athan Kuliopulos
Journal:  J Biol Chem       Date:  2012-05-09       Impact factor: 5.157

6.  Association between promoter polymorphisms of matrix metalloproteinase-1 and risk of gastric cancer.

Authors:  Qisong Peng; Yong Xu
Journal:  Onco Targets Ther       Date:  2015-09-10       Impact factor: 4.147

7.  Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis.

Authors:  Ji Wang; Chenyang Ye; Demin Lu; Yongxia Chen; Yunlu Jia; Xiaogang Ying; Hanchu Xiong; Wenhe Zhao; Jichun Zhou; Linbo Wang
Journal:  Oncotarget       Date:  2017-08-24

Review 8.  The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.

Authors:  Ruth M Escalona; Emily Chan; George Kannourakis; Jock K Findlay; Nuzhat Ahmed
Journal:  Int J Mol Sci       Date:  2018-02-02       Impact factor: 5.923

Review 9.  Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis.

Authors:  Marek Z Wojtukiewicz; Dominika Hempel; Ewa Sierko; Stephanie C Tucker; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

10.  Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer.

Authors:  Tejaswini Subbannayya; Pamela Leal-Rojas; Mustafa A Barbhuiya; Remya Raja; Santosh Renuse; Gajanan Sathe; Sneha M Pinto; Nazia Syed; Vishalakshi Nanjappa; Arun H Patil; Patricia Garcia; Nandini A Sahasrabuddhe; Bipin Nair; Rafael Guerrero-Preston; Sanjay Navani; Pramod K Tiwari; Vani Santosh; David Sidransky; T S Keshava Prasad; Harsha Gowda; Juan Carlos Roa; Akhilesh Pandey; Aditi Chatterjee
Journal:  BMC Cancer       Date:  2015-11-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.